In the UAE, G42 is also trialling the world's first phase III clinical trial of a Covid-19 inactivated vaccine
Abu Dhabi-based tech firm Group 42 has penned an agreement with Israel’s Rafael Advanced Defense Systems and Israel Aerospace Industries (IAI) to explore ways to work together to combat Covid-19, it was announced on Thursday.
According to the UAE’s state-run WAM news agency, the Memorandum of Understanding (MoU), executives from each company signed the agreement during a video teleconference between the UAE and Israel.
In a statement carried by the UAE’s state-run WAM news agency, Group 42 CEO Peng Xiao said that the company embraces international cooperation “as a way to develop new and innovative technological solutions for the public good.”
“The UAE has led by example in the global collaborative effort to defeat the Covid-19 pandemic, and our company is privileged to follow the lead and share resources and expertise with Rafael and IAI for such a significant cause,” he added.
As part of the agreement, the companies will share knowledge, human and technological assets in the hopes of delivering solutions that safeguard the public from the Covid-19 pandemic.
In the UAE, G42 is also trialling the world’s first phase III clinical trial of a Covid-19 inactivated vaccine, under the supervision of Abu Dhabi’s Department of Health.